Clinical Trial Update: Pemetrexed Disodium With or Without Sorafenib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating pemetrexed disodium with or without sorafenib as second-line therapy in stage IIIB/IV non-small cell lung cancer has completed and post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Pemetrexed disodium (Pemetrexed disodium)
• Sorafenib (Sorafenib)

Snippet

Sponsor: Alliance for Clinical Trials in Oncology | Conditions: Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2017-01-31